[1] HUANG C, WANG Y, LI X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, pii:S0140-6736(20)30183-5.DOI:10.1016/S0140-6736(20)30183-5.
[2] COHEN J. Chinese researchers reveal draft genome of virus implicated in Wuhan pneumonia outbreak. Washington, DC:American Association for the Advancement of Science [EB/OL]. (2020-01-11)[2020-01-21].https://www.sciencemag.org/news/2020/01/chinese-researchers-reveal-draft-genomevirus-implicated-wuhan-pneumonia-outbreak.
[3] WORLD HEALTH ORGANIZATION. Novelcoronavirus-China[EB/OL].(2020-01-12)[2020-01-19].http://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/.
[4] ZHAO Y, ZOU L, WANG L, et al. Management strategy of SARA-CoV-2 infection in pregnancy [J]. Chin J Obstet Gynecol(中华妇产科杂志),2020,55(2):75-76.
[5] WANG X Y, WU J, LU X H, et al. Recommendations for management strategies of pregnant women with new coronavirus (2019-nCoV) infection in Henan Province [J/OL]. J Zhengzhou Univ, Med Sci(郑州大学学报,医学版),2020. DOI:10.13705/j.issn.1671-6825.2020.01.167
[6] MATERNAL AND FETAL EXPERTS COMMITTEE, CHINESE PHYSICIAN SOCIETY OF OBSTETRICS AND GYNECOLOGY, CHINESE MEDICAL DOCTOR ASSOCIATION,et al. Proposed management of COVID-19 during pregnancy and puerperium[J]. Chin J Perinat Med, 2020, 23 (2): 73-79.
[7] NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA. Guidelines for diagnosis and treatment of coronavirus disease 2019 trail version 6 [EB/OL]. National Health Commission of the People's Republic of China, 2020. (2020-03-07) [2020-04-28]. http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7/files/4132bf035bc242478a6eaf157eb0d979.pdf.
[8] LIU J X, CHEN W M. Adverse reactions of interferon in clinical application[J]. Public Med Forum Mag(基层医学论坛), 2010, 14(22):745-746.
[9] YANG H, ZHOU G Q, HE F C. The mechanism, efficacy and influencing factor of interferon-α therapy in chronic hepatitis B[J]. Inter J Epidemiol Infect Dis(国际流行病学传染病学杂志),2006, 33(4):247-250.
[10] HUANG Z H, YU G Z. Comparative study of curative effect between interferon and ganciclovir in the treatment of infants with respiratory syncytial virus pneumonia[J]. J Clin Pulm Med(临床肺科杂志), 2014,19(1):46-48.
[11] DONG A Q, XU Y. Research progress of pulmonary inhalation delivery System [J]. Jiangxi Med J(江西医药), 2007, 42(1):82-85.
[12] MA J G,ZHA L. Short-term effect and long-term prognosis evaluation of interferon a1b in treatment of children with bronchiolitis[J]. J Clin Pulm Med(临床肺科杂志), 2019,24(10):1842-1846.
[13] LI Y R, XIE W. Adverse reactions and treatment of interferon alpha-part of the interpretation of chronic hepatitis B prevention and treatment guidelines[J]. Chin J Med(中国医刊), 2007,42(11):5-7.
[14] WU L,XIE W. Adverse reactions of interferon-α and its countermeasures[J]. Chin Clin Dr(中国临床医生杂志), 2012,40(4):18-20.
[15] LI M H, XIE Y. Expert consensus on clinical management of adverse reactions in interferon-αtherapy for chronic viral hepatitis[J]. Chin J Exp Clin Infect Dis, Electron Ed(中华实验和临床感染病杂志,电子版), 2014,30(11):1106-1111.
[16] ZHANG M M, ZHANG H, LI Y, et al. Clinical observation of myelosuppression induced by interferon combined with ribavirin in the treatment of chronic hepatitis C and its symptomatic treatment[J]. Pharm Care Res(药学服务与研究), 2017,17(1):43-45.
[17] WILLIAM G P, SUSANNA N, ARTHUR Y K, et al. IDSA/AASLD response to cochrane review on direct-acting antivirals for hepatitis C[J]. Clin Infect Dis, 2017, 65(11):1773-1775.
[18] REGIERER A C, SCHULZ C O, KUEHNHARDT D, et al. Interferon-α therapy for chronic myeloid leukemia during pregnancy[J]. Am J Hematol, 2006, 81(2):149-150.
[19] YOSHIDA Y, KATSURADA T, NAKABOU Y, et al. Efficacy of interferon-alpha in essential thrombocythemia during pregnancy[J]. An Hematol, 2017, 96(5):877-878.
[20] BROJENI P Y, MATOK I, BOURNISSEN F G, et al. A systematic review of the fetal safety of interferon alpha[J]. Reprod Toxicol, 2012, 33(3):265-268.
[21] FRITZ M, VATS K, GOYAL R K. Neonatal lupus and lUGR following alpha-interferon therapy during pregnancy[J]. J Perinatol,2005, 25(8):552-554
[22] SUN D L,ZHENG C H. Safety of anti-hepatitis B virus therapy during pregnancy and lactation [J]. Chin J Mod Appl Pharm(中国现代应用药学), 2017,34(11):1635-1642.
[23] PONS J C, LEBON P, FRYDMAN R, et al. Pharmacokinetics of interferon-alpha in pregnantwomen and fetoplacental passage[J]. Fetal Diagn Ther, 1995,10(1):7-10.
[24] FDALABEL. Interferon alfa-2a, recombinant injection[EB/OL]. US FDA,2006.(2006-08-29) [2020-04-12]. https://www.fda.gov/drugs/drug safety and availability.
[25] FDALABEL. Peginterferon alfa-2a injection[EB/OL].US FDA,2017. (2017-10-13) [2020-04-12]. https://www.fda.gov/drugs/drug safety related labeling changes srlc database.
[26] JIANG X X. Study on synthesis of new HIV protease inhibitors[D]. Shanghai:Tongji University, 2003.
[27] ZHANG X Y, LIU Z Y, LI T S. Progress in clinical application of lopinavir / ritonavir against human immunodeficiency virus[J]. Natl Med J China(中华医学杂志), 2015,95(35):2893-2896.
[28] KIM U J, WON E J, KEE S J, et al. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome[J]. Antivir Ther, 2016, 21(5):455-459.
[29] MEYER B, BASRA A, ABERLE S, et al. MERS-COV disease associated adrs-a case report[J]. Crit Care Med, 2015, 43(12):308.
[30] CHU M C, CHENG V C, HUNG I F, et al. Role of lopinavir/ritonavir in the treatment of SARS:initial virological and clinical findings[J]. Thorax, 2004, 59(3):252-256.
[31] JIANG H, DENG H F, WANG Y,et al. The possibility of using lopinave /litonawe (LPV/r) as treatment for novel coronavirus(2019-nCov)pneumonia: a quick systematic review based on earlier coronavirus clinical studies[J]. Chin J Emerg Med(中华急诊医学杂志), 2020,29(2):182-186.
[32] ZHANG Y L, LIU Z Y. Progress of clinical application of lopinavir / ritonavir in the treatment of HIV-1 infection[C].The 13th National Conference on Infectious Diseases of Chinese Medical Association,2014.
[33] FDALABEL. Lopinavir and ritonavir tablet,oral solution [EB/OL]. US FDA, 2015. (2015-11-10) [2020-04-12]. https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/
[34] PASLEY M V, MARTINEZ M, HERMES A, et al. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review[J]. Aids Rev, 2013, 15(1):38-48.
[35] PERRY M E, TAYLOR G P, SABIN C A, et al. Lopinavir and atazanavir in pregnancy:comparable infant outcomes, virological efficacies and preterm delivery rates[J]. Hiv Med, 2016,17(1):28-35.
[36] ROBERTS S S, MARTINEZ M, COVINGTON D L, et al. Lopinavir/ritonavir in pregnancy[J]. J Acquir Immune Defic Syndr, 2009,51(4):456-461.
[37] CHRISTIANA S, ADRIANA W, FORSTER J E, et al. Maternal lopinavir/ritonavir is associated with fewer adverse events in infants than nelfinavir or atazanavir[J]. Infect Dis Obstet Gynecol, 2016, 2016:1-9.
[38] BRITES C, NÓBREGA I, LUZ E, et al. Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women[J]. HIV Clin Trials, 2018,19(3):94-100.
[39] WHITLEY R J, KIMBERLIN D W. Treatment of viral infections during pregnancy and the neonatal period[J]. Clin Perinatol, 1997, 24(1):267-283.
[40] GHAZI SULIMAN M A, OGUNGBENRO K, KOSMIDIS C, et al. The effect of veno-venous ECMO on the pharmacokinetics of ritonavir, darunavir, tenofovir and lamivudine[J]. J Crit Care,2017,40:113-118.
[41] YAO Y M,MU J,SUN J, et al. Progress on pharmacokinetics of lopinavir[J]. J Pharm Pract(药学实践杂志),2012,30(5):20-23.
[42] GORNY M, ROHM S, LAER S, et al. Pharmacogenomic adaptation of antiretroviral therapy:overcoming the failure of lopinavir in an African infant with CYP2D6 ultrarapid metabolism[J]. Eur J Clin Pharmacol, 2010,66(1):107-108.
[43] SALMAN S, BAIWOG F, PAGE-SHARP M, et al. Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling[J]. Int J Antimicrob Agents, 2017, 50(4):542-551.
[44] KLINGER G, MORAD Y, WESTALL C A, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases[J]. Lancet, 2001, 358(9284):813-814.
[45] CHEN Y, FENG X,YANG H, et al. Principles and contraindications of commonly used Chinese patent medicines for diseases in pregnancy[J]. Chin J Fam Plann Gynecotokol(中国计划生育和妇产科), 2015,7(2):5-8.
[46] WANG Q L,CHENG Y B. Statistics and analysis of the variations of Chinese patent medicines related to contraindications of pregnancy in the pharmacopoeia of the People's Republic of China in 2010[J]. Chin J Inf Tradit Chin Med(中国中医药信息杂志), 2011,18(10):100-102.